CN1839842A - Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient - Google Patents

Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient Download PDF

Info

Publication number
CN1839842A
CN1839842A CN 200610000963 CN200610000963A CN1839842A CN 1839842 A CN1839842 A CN 1839842A CN 200610000963 CN200610000963 CN 200610000963 CN 200610000963 A CN200610000963 A CN 200610000963A CN 1839842 A CN1839842 A CN 1839842A
Authority
CN
China
Prior art keywords
levosimendan
clear liquid
qualified
yellow clear
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 200610000963
Other languages
Chinese (zh)
Inventor
王成
韩晓彤
代丽萍
吴庆江
李思成
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Silvio Sanjiang Pharmaceutical Co Ltd
CHENGDU ENTRY SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT Co Ltd
Original Assignee
Sichuan Silvio Sanjiang Pharmaceutical Co Ltd
CHENGDU ENTRY SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Silvio Sanjiang Pharmaceutical Co Ltd, CHENGDU ENTRY SCIENTIFIC AND TECHNOLOGICAL DEVELOPMENT Co Ltd filed Critical Sichuan Silvio Sanjiang Pharmaceutical Co Ltd
Priority to CN 200610000963 priority Critical patent/CN1839842A/en
Publication of CN1839842A publication Critical patent/CN1839842A/en
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a pharmaceutical composition, wherein each unit dosage comprises: (1) 5-50mg of Levosimendan or its pharmaceutically acceptable salt, (2) 10-200mg of Solutol HS 15, (3) 0.1-1000ml of medicinal solvent.

Description

A kind of contain levosimendan or its pharmaceutically acceptable salt as the pharmaceutical composition of active component
Technical field
The present invention relates to a kind of pharmaceutical preparation, a kind of pharmaceutical solutions of particularly anti-heart failure medicine levosimendan.The safety of intravenous administration and the problem of stability have been solved.
Background technology
Levosimendan, chemical name [(-)-[4-(1,4,5,6-tetrahydrochysene-4-methyl-6-oxo-3-pyridazinyl) phenyl] hydrazono-] Cyanoacetyl-Cyacetazid, be a kind of be effective medicine in the treatment of congestive heart failure.Levosimendan is effectively in the treatment of heart failure, and Ca-dependent significant and that troponin interrelates is arranged. levosimendan is expressed from the next:
Levosimendan is a kind of medicine that is insoluble in water, Sundberg, 5. etc., and at Am.J.Cardiol., 1995; Put down in writing the hematodinamics effect of levosimendan among the 75:1061-1066 to human body.Sandell, E-P. etc., at J.cardiovasc.Pharmacol., 26 (suppl.1) have put down in writing the pharmacokinetics of levosimendan behind human vein and the oral administration in 557-562,1995.WO93/21921 has put down in writing the purposes of levosimendan aspect the treatment myocardial ischaemia.WO98/01111 has put down in writing the transdermal composition of levosimendan.Clinical research confirmation the beneficial effect of levosimendan to the heart failure patient.Drug solution by the levosimendan of Orion-Yhtyma OY research and development in 2000, and apply for a patent in China, but its used solubilizing agent polyethylene pyrrole Lip river alkane ketone or other surfactant prove that clinically tool all has the blood coagulation side effect, brings the treatment risk to the patient.
The levosimendan pharmaceutical solutions adopts ethanol as solvent in addition in the prior art, or adds other organic solvents, or the levosimendan enclose is made methods such as dissolving, and above method does not all solve the dissolubility of preparation and the problem of stability fully.
Solutol HS15 is a kind of solubilizing agents for drugs that is provided by BASF AG, is incorporated in the Deutscher Arzneibucs.Solutol HS15 is a kind of Polyethylene Glycol (PEG) 12-hydroxy stearic acid ester, and structure is as follows:
Solutol Outward appearance is light yellowish-white paste under the HS15 room temperature.It and used in the past solubilizing agent such as CremophorEL, Cremophor RH40, Cremophor 60 or Tweens, as Tween 80, Tween 65, Tween 20 or wheat pool class, as Myrj 52 or Labrafil M 1944 CS (Oleoyl Macrogo1-6 glycerides), LabrafilM 2125 CS (Linoleoyl macrogol-6 glycerides), Labrasol (Caprylocaproylmacrogol-8 glycerides), Lauroglycol 90 (Propylene glycol monolaurate), Plurololeique CC 497 (Polyflyceryl-6 dioleate) solubilization-aid effect is similar.
With Solutol HS15 is used to prepare the levosimendan pharmaceutical solutions, and report is not arranged at present.
In order to improve the bioavailability of levosimendan, dissolubility, improve the medicine stability of preparation, the present invention is carrying out the levosimendan medicine on the basis of solubilization studies, combination to many kinds of surfactants, surface activity auxiliary agent, solubilizing agent, oily components is studied, and finds to use Solutol HS15 can make medicine more stable in solution, and dissolubility is better, the appearance of catabolite in the restriction storage life, the haemolysis that is produced when reducing intravenous injection or the harm of other some side effect.
Summary of the invention:
The invention provides a kind of levosimendan pharmaceutical solutions prescription,
The present invention selects ethanol for use, propylene glycol, and glycerol, and other pharmaceutically acceptable organic solvent is as the levosimendan solvent, with Solutol HS15 is solubilizing agent, Solutol The HLB value of HS15 is 14 to 16, is a kind of hydrophilic surfactant active.
In the compositions of the present invention, select Solutol for use The HS15HLB value is 14 to 16 the medicinal hydrophilic surfactant active solubilizing agent for fat-soluble medicine, to promote that hydrophilic and oleophilic moiety reaches balance in the compositions, forms stable drug solution.This class HLB value is that 14 to 16 surfactant is Solutol HS15, than castor oil derivatives, as Cremophor EL, Cremophor RH40, Cremophor 60 or Tweens, as Tween 80, Tween 65, Tween 20 or wheat pool class, better as Myrj 52 lyotropy, more can avoid the precipitation of active component, other medicinal surfactant of injection stage that the haemolysis side effect is lower.
Levosimendan pharmaceutical solutions of the present invention wherein contains
(a) as the levosimendan of active component, every dose contains 5-50mg, preferably 10-25mg
(b) solubilizing agent Solutol HS15, every dose contains 10-200mg, preferably 20-100mg
(c) medicinal solvent, every dose contains 0.1-1000ml, preferably 0.2-10ml
Levosimendan pharmaceutical solutions of the present invention can be prepared into different dosage forms as required, as dosage forms such as injection, frozen powder for injection, soft capsule, ointment, eye drop, oral liquids.
The above every dose unit form that is meant above dosage form, as each injection, each soft capsule.
Can be according to the different requirements of each dosage form, can not add entry or add suitable water or other solvent or add suitable pharmaceutical excipient,
Wherein said medicinal solvent is selected from ethanol, propylene glycol, glycerol, and other pharmaceutically acceptable organic solvent.Preferably: ethanol, propylene glycol.
Wherein said suitable pharmaceutical excipient comprises the pH value regulator, as pharmaceutically acceptable pH value regulator, is routine or known substance, and its Pka is in the 2-5 scope.As citric acid or phosphate, citrate, lactate, acetate etc., its consumption is determined as required, regulates PH between 4-9, and consumption is generally in 1.1%, preferably: in 1.0%.
Levosimendan of the present invention also comprises the pharmaceutically acceptable salt of levosimendan.
The most preferred prescription composition of the present invention is listed in the embodiment of the invention.
Prescription of the present invention is selected Solutol for use in forming HS15 makes the present invention more stable than prior art as surfactant, and toxicity is lower, and patient's medication is safer, more is applicable to injecting drug use.
Another unique distinction of the present invention is, different use according to compositions can add water, also can add a certain proportion of water, as in levosimendan compositions liquid, adding a certain proportion of water, can reduce compositions and solidify or form the temperature of floccule, make it under relatively low temperature, still can keep haze-free.These characteristics also can be used for the preparation of hydrophilic ointment and eye drop.Simultaneously according to clinically different demands, the compositions that contains levosimendan or its pharmaceutically acceptable salt of the present invention can be prepared into gelatin and be encapsulated as soft capsule, also can be made into dosage forms such as ointment, oral liquid, injection, injection freeze-dried powder and liniment.
The preparation method of different dosage form of the present invention can require according to the galenic pharmacy routine techniques of said preparation to carry out.As the preparation of injection is levosimendan or pharmaceutically acceptable salt with recipe quantity, and Solutol HS15, and medicinal solvent and pharmaceutical excipient mix, and make dissolving, and packing promptly.
Following data declaration beneficial effect of the present invention by experiment:
The drug solution (abbreviation Comparative formulation) of the contrast levosimendan that injection water injection that levosimendan compositions of the present invention and embodiment 1 are made and CN1203855C patent prescription make and the stability that the injection that makes is put illumination (4500lx), high temperature (60 ℃), high temperature (40 ℃) and low temperature (4 ℃) under thereof are investigated investigation data such as following table 1.
Table 1: the stability contrast of levosimendan compositions of the present invention and Comparative formulation
PROJECT TIME (my god) Character Clarity Related substance % Content %
The present composition Comparative formulation The present composition Comparative formulation The present composition Comparative formulation The present composition Comparative formulation
Illumination 4500LX 0 Yellow clear liquid Yellow clear liquid Qualified Qualified 0.22 0.24 99.78 99.76
5 Yellow clear liquid Yellow clear liquid Qualified Qualified 0.53 0.55 99.47 99.45
10 Yellow clear liquid Yellow clear liquid Qualified Qualified 1.58 1.63 98.42 98.37
60 ℃ of high temperature 0 Yellow clear liquid Yellow clear liquid Qualified Qualified 0.22 0.24 99.78 99.76
5 Yellow clear liquid Yellow clear liquid Qualified Qualified 6.27 6.39 93.72 93.61
10 Yellow clear liquid Yellow clear liquid Qualified Qualified 7.69 7.90 92.31 92.10
40 ℃ of high temperature 0 Yellow clear liquid Yellow clear liquid Qualified Qualified 0.22 0.24 99.78 99.76
5 Yellow clear liquid Yellow clear liquid Qualified Qualified 0.61 0.63 99.39 99.37
10 Yellow clear liquid Yellow clear liquid Qualified Qualified 1.30 1.41 98.70 98.59
4 ℃ of low temperature 0 Yellow clear liquid Yellow clear liquid Qualified Qualified 0.22 0.24 99.78 99.76
5 Yellow clear liquid Yellow clear liquid Qualified Qualified 0.22 0.23 99.78 99.77
10 Yellow clear liquid Yellow clear liquid Qualified Qualified 0.24 0.25 99.76 99.75
By table as seen, compositions of the present invention, under illumination (4500lx), high temperature (60 ℃), high temperature (40 ℃) condition, the drug solution of the contrast levosimendan that makes with CN1203855C patent prescription is compared better, and related substance and content are more or less the same, and illustrate that levosimendan compositions of the present invention is equally stable than the drug solution of the levosimendan of CN1203855C patent.Each 5ml of drug solution of the injection composition that example 1 is made and the levosimendan of CN1203855C patent respectively with 100ml5% glucose injection and 0.9% sodium chloride injection in compatibility, detect 8 hours in the mass change situation, the results are shown in Table 2.
Table 2: compatibility experimental result in the drug solution of the levosimendan of ejection preparation that pharmaceutical composition of the present invention makes and CN1203855C patent and glucose injection and 0.9% sodium chloride injection
Time h Character PH value Clarity Related substance (%)
5% glucose injection 0.9% sodium chloride injection 5% glucose injection 0.9% sodium chloride injection 5% glucose injection 0.9% sodium chloride injection 5% glucose injection 0.9% sodium chloride injection
Ejection preparation of the present invention
0 Faint yellow clear liquid Faint yellow clear liquid 3.89 3.45 Qualified Qualified 0.23 0.24
2 Faint yellow clear liquid Faint yellow clear liquid 3.89 3.45 Qualified Qualified 0.23 0.25
4 Faint yellow clear liquid Faint yellow clear liquid 3.90 3.44 Qualified Qualified 0.26 0.27
6 Faint yellow clear liquid Faint yellow clear liquid 3.91 3.46 Qualified Qualified 0.34. 0.37
8 Faint yellow clear liquid Faint yellow clear liquid 3.89 3.45 Qualified Qualified 0.51 0.59
Comparative formulation
0 Faint yellow clear liquid Faint yellow clear liquid 3.88 3.43 Qualified Qualified 0.24 0.23
2 Faint yellow clear liquid Faint yellow clear liquid 3.88 3.45 Qualified Qualified 0.24 0.23
4 Faint yellow clear liquid Faint yellow clear liquid 3.89 3.41 Qualified Qualified 0.25 0.26
6 Faint yellow clear liquid Faint yellow clear liquid 3.87 3.42 Qualified Qualified 0.26 0.26
8 Faint yellow clear liquid Faint yellow clear liquid 3.90 3.43 Qualified Qualified 0.35 0.36
0 Faint yellow clear liquid Faint yellow clear liquid 3.88 3.43 Qualified Qualified 0.51 0.60
The result shows: compatibility in injection that levosimendan compositions of the present invention is made and 5% glucose injection and 0.9% sodium chloride injection, and stable equally with the drug solution of the levosimendan of CN1203855C patent in the 8h.
The drug solution (being called for short Comparative formulation x) of the contrast levosimendan that frozen powder for injection injection that levosimendan compositions of the present invention and embodiment 3 are made and CN1203855C patent prescription make and the stability that the injection that makes is put under illumination (4500lx), high temperature (60 ℃), high temperature (40 ℃) and the low temperature (4 ℃) thereof are investigated
Investigate data such as following table.
Table 3: the stability contrast of levosimendan freeze-dried powder of the present invention and Comparative formulation
PROJECT TIME (my god) Character Clarity Related substance % Content %
Freeze-dried powder of the present invention Comparative formulation Freeze-dried powder of the present invention Comparative formulation Freeze-dried powder of the present invention Comparative formulation Freeze-dried powder of the present invention Comparative formulation
Illumination 4500LX 0 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.26 0.24 99.74 99.76
5 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.41 0.55 99.59 99.45
10 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 1.18 1.63 98.82 98.37
60 ℃ of high temperature 0 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.26 0.24 99.74 99.76
5 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 5.07 6.39 94.93 93.61
10 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 6.52 7.90 93.48 92.10
40 ℃ of high temperature 0 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.26 0.24 99.74 99.76
5 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.50 0.63 99.50 99.37
10 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.81 1.41 99.19 98.59
4 ℃ of low temperature 0 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.26 0.24 99.74 99.76
5 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.26 0.23 99.74 99.77
10 Yellow lyophilizing block Yellow clear liquid Qualified Qualified 0.27 0.25 99.73 99.75
By table as seen, composite freeze-dried powder of the present invention, under illumination (4500lx), high temperature (60 ℃), high temperature (40 ℃) condition, the drug solution of the contrast levosimendan that makes with CN1203855C patent prescription is compared better, related substance and content are more or less the same, and illustrate that levosimendan compositions of the present invention is equally stable than the drug solution of the levosimendan of CN1203855C patent.Each 5ml of drug solution of one of the freeze-dried powder that example 3 is made and the levosimendan of CN1203855C patent respectively with 100ml5% glucose injection and 0.9% sodium chloride injection in compatibility, detect 8 hours in the mass change situation, the results are shown in Table 4.
Table 4: compatibility experimental result in the drug solution of the levosimendan of frozen powder for injection pin of the present invention and CN1203855C patent and glucose injection and 0.9% sodium chloride injection
Time h Character PH value Clarity Related substance (%)
5% glucose injection 0.9% sodium chloride injection 5% glucose injection 0.9% sodium chloride injection 5% glucose injection 0.9% sodium chloride injection 5% glucose injection 0.9% sodium chloride injection
Ejection preparation of the present invention
0 Faint yellow clear liquid Faint yellow clear liquid 7.52 7.40 Qualified Qualified 0.28 0.29
2 Faint yellow clear Faint yellow clear and bright 7.57 7.39 Qualified Qualified 0.29 0.31
Prescribed liquid Liquid
4 Faint yellow clear liquid Faint yellow clear liquid 7.58 7.40 Qualified Qualified 0.30 0.33
6 Faint yellow clear liquid Faint yellow clear liquid 7.59 7.43 Qualified Qualified 0.31. 0.35
8 Faint yellow clear liquid Faint yellow clear liquid 7.60 7.42 Qualified Qualified 0.49 0.52
Comparative formulation
0 Faint yellow clear liquid Faint yellow clear liquid 3.88 3.43 Qualified Qualified 0.24 0.23
2 Faint yellow clear liquid Faint yellow clear liquid 3.88 3.45 Qualified Qualified 0.24 0.23
4 Faint yellow clear liquid Faint yellow clear liquid 3.89 3.41 Qualified Qualified 0.25 0.26
6 Faint yellow clear liquid Faint yellow clear liquid 3.87 3.42 Qualified Qualified 0.26 0.26
8 Faint yellow clear liquid Faint yellow clear liquid 3.90 3.43 Qualified Qualified 0.35 0.36
0 Faint yellow clear liquid Faint yellow clear liquid 3.88 3.43 Qualified Qualified 0.51 0.60
The result shows: compatibility in levosimendan freeze-dried powder of the present invention and 5% glucose injection and 0.9% sodium chloride injection, and more stable with the drug solution of the levosimendan of CN1203855C patent in the 8h, satisfy the clinical application requirement.
Advantage of the present invention also shows:
(1) need not to use hydryllin and corticoid before low histamine release-art;
(2) low haemolysis;
(3) higher physiological tolerance; The used vapour sterilization need not expensive aseptic manufacturing process;
(4) low viscosity, high solubilising power-make the injection of low capacity high dose become possibility, even low viscosity when high concentration, 30% resolution solution also can painless administration; Stimulation and the some other serious problems that cause owing to used adjuvant high viscosity before solving to vascular system.
The present invention improves levosimendan dissolubility and water stability thereof, further makes its stability that has better chemistry and physics in the storage life that prolongs, and reduces the hemolytic of clinical injection medication, makes it be more suitable for intravenously administrable.Pharmaceutical composition of the present invention has stronger stability, and safe and effective especially as transfusion or injection solution or infusion concentrated solution.
The specific embodiment
The following examples will be made a more detailed description to the present invention.But, should be understood that, these embodiment be not be used for limiting of the present invention.
Embodiment 1 levosimendan injection
Amounts of components (g)
Levosimendan 2.5g
SolutolHS15 10g
Anhydrous citric acid 2g
Dehydrated alcohol adds to 1000ml
In aseptic preparation container, citric acid, Solutol  HS15 and levosimendan are dissolved in the dehydrated alcohol with the preparation concentrated solution.(0.22 μ m) filters the gained tank solution by sterile filters.The sterilizing methods of this product is aseptic filtration, can not adopt autoclaving because alcoholic solution has the danger of blast.Solution sterile filling in bulk after the aseptic filtration in the injection bottle, and is covered transfusion with the sealing of dacron membrane rubber stopper with adding.
Embodiment 2 levosimendan oral liquids
Amounts of components
Levosimendan 12.5mg
SolutolHS15 30mg
Dehydrated alcohol 2.5ml
Semen Maydis oil " 10ml
Make 12ml
The levosimendan compositions is mixed with Semen Maydis oil, under stirring condition, stir evenly, make clarifying oily liquids, can be as oral liquid, or make soft capsule as soft capsule content.
Embodiment 3
Amounts of components
Levosimendan 12.5mg
Mannitol 280mg
SolutolHS15 50mg
0.2mol/L sodium hydrogen phosphate 1.46ml
0.2mol/L sodium dihydrogen phosphate 0.14ml
Water for injection adds to 3ml
Get levosimendan, Solutol  HS15, mannitol adds sodium hydrogen phosphate and sodium dihydrogen phosphate, stirring makes dissolving (PH is 7.8) fully, adds active carbon 3mg, continues to stir 30min, take off charcoal, add the injection water and be settled to 3ml, the degerming of 0.22um microporous filter membrane fine straining.Under aseptic condition, gained solution is put in the aseptic cillin bottle, put and carry out lyophilization in the freezer dryer, seal.Promptly get xanchromatic levosimendan freeze-dried powder preparation of the present invention.

Claims (10)

  1. A levosimendan or its pharmaceutically acceptable salt it is characterized in that as the pharmaceutical preparation of active component, comprise following ingredients:
    (a) levosimendan or its acceptable salt pharmaceutically, every dose contains 5-50mg,
    (b) Solutol  HS 15, every dose contains 10-200mg
    (c) medicinal solvent, every dose contains 0.1-1000ml.
  2. 2, the pharmaceutical preparation of claim 1 is characterized in that, also comprises pharmaceutical excipient, is selected from pH value regulator, antioxidant, flavoring agent, penetration enhancer, antiseptic.
  3. 3, the pharmaceutical preparation of claim 2 is characterized in that, wherein said have the pH value regulator to be selected from pharmaceutically acceptable organic acid or salt.
  4. 4, the pharmaceutical preparation of claim 3 is characterized in that, wherein said organic acid is selected from citric acid, lactic acid, and wherein said salt is selected from phosphate, citrate, lactate, acetate.
  5. 5, the pharmaceutical preparation of claim 1 is characterized in that, described medicinal solvent is selected from water, ethanol, propylene glycol, glycerol, buffer solution.
  6. 6, the pharmaceutical preparation of claim 1 is characterized in that, comprises following ingredients:
    (a) levosimendan or its acceptable salt pharmaceutically, every dose contains 10-25mg
    (b) Solutol  HS 15, every dose contains 20-100mg
    (c) medicinal solvent, every dose contains 0.2-10ml
    (d) organic acid, percentage by weight are 0.02-1.0%.
  7. 7, the pharmaceutical preparation of claim 1 is characterized in that, described preparation is selected from injection, soft capsule, ointment, oral liquid and liniment.
  8. 8, the pharmaceutical preparation of claim 1 is characterized in that, described preparation is an injection.
  9. 9, the pharmaceutical preparation of claim 1 is characterized in that, is made up of following prescription:
    Levosimendan 2.5g
    Solutol HS 15 10g
    Anhydrous citric acid 2g
    Dehydrated alcohol adds to 1000ml.
  10. 10, the pharmaceutical preparation of claim 1 is characterized in that, is made up of following prescription:
    Levosimendan 12.5mg
    Solutol HS 15 30mg
    Dehydrated alcohol 2.5ml
    Semen Maydis oil 10ml.
CN 200610000963 2006-01-16 2006-01-16 Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient Pending CN1839842A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200610000963 CN1839842A (en) 2006-01-16 2006-01-16 Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200610000963 CN1839842A (en) 2006-01-16 2006-01-16 Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient

Publications (1)

Publication Number Publication Date
CN1839842A true CN1839842A (en) 2006-10-04

Family

ID=37029146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200610000963 Pending CN1839842A (en) 2006-01-16 2006-01-16 Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient

Country Status (1)

Country Link
CN (1) CN1839842A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101366696B (en) * 2008-10-16 2012-04-11 姚定全 Medicament composition for water-soluble injection of paclitaxel, preparation method and uses thereof
WO2017077032A1 (en) * 2015-11-06 2017-05-11 Carinopharm Gmbh Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
CN111548310A (en) * 2020-05-12 2020-08-18 成都欣捷高新技术开发股份有限公司 Levosimendan sodium crystal form and preparation method thereof

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101366696B (en) * 2008-10-16 2012-04-11 姚定全 Medicament composition for water-soluble injection of paclitaxel, preparation method and uses thereof
WO2017077032A1 (en) * 2015-11-06 2017-05-11 Carinopharm Gmbh Improved formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
CN108289832A (en) * 2015-11-06 2018-07-17 卡利努法姆股份有限公司 For carrying out the Levosimendan of intravenously administrable with infusion or injection form and being transfused the improvement formula of concentrate
US10507179B2 (en) 2015-11-06 2019-12-17 Carinopharm Gmbh Formulations of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
EA034565B1 (en) * 2015-11-06 2020-02-20 Каринофарм Гмбх Compositions of levosimendan for intravenous administration as infusion or injection and of infusion concentrate
CN108289832B (en) * 2015-11-06 2021-08-31 卡利努法姆股份有限公司 Improved formulations of levosimendan and infusion concentrates for intravenous administration in infusion or injection form
CN111548310A (en) * 2020-05-12 2020-08-18 成都欣捷高新技术开发股份有限公司 Levosimendan sodium crystal form and preparation method thereof
CN111548310B (en) * 2020-05-12 2021-07-02 成都欣捷高新技术开发股份有限公司 Levosimendan sodium crystal form and preparation method thereof

Similar Documents

Publication Publication Date Title
CN1112924C (en) Rapamycin formulation for IV injection
CN1203855C (en) Pharmaceutical solutions for levosimendan
CN1623543A (en) Organic compounds
CN1649603A (en) Aqueous compositions containing metronidazole
CN1170533C (en) Pharmaceutically stable oxaliplatinum preparation for parenteral administration
CN1686116A (en) Levo ornidazole vein administration agent and its preparation method
CN1368891A (en) Moxilfloxacin formulation containing common salt
CN101056616A (en) The injection of tacrolimus
CN1283235C (en) Clear and stable propofol composition
CN101961311B (en) 5alpha-androstane (alkyl)-3beta,5,6beta-triol injection and preparation method thereof
CN1706386A (en) Enrofloxacin suspension and its prepn process
CN1839842A (en) Pharmaceutical composition containing levosimendan or its pharmaceutically acceptable salt as active ingredient
CN112402371B (en) Rudesiwei injection and preparation method thereof
CN1897940A (en) Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same
CN101053557A (en) Noradrenaline bitartrate medicine composition frozen dried powder injection
CN1839800A (en) Vinorelbine Bitartrate lipsome freeze-drying powder injection and its preparation method
CN100336507C (en) Nimoldipine new nano liposome, its precursor freeze dryed matter and its preparing method
CN1186094C (en) Piracetam medicine composition with function of promoting thinking and memory and its prepn
CN1263458C (en) Candex kind object polyene large cyslic lactone kind liposome composition and its preparation method
CN1478465A (en) Biphenyl diester liquid medicinal composition containing fat
CN1771932A (en) Castor oil injection of low content polyethenoxy ether and ethanol injection of low content taxol
CN1535679A (en) Medicine composition containing taxol substance and its preparation method
CN1939328A (en) Puerarin injection
CN1565446A (en) Freeze-drying fluconazole injection and its preparation method
CN1732954A (en) Freeze dry emulsion of prostaglandin for injection and method for preparing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication